Literature DB >> 12165490

TCR/CD3 down-modulation and zeta degradation are regulated by ZAP-70.

Céline Dumont1, Nicolas Blanchard, Vincenzo Di Bartolo, Nathalie Lezot, Evelyne Dufour, Sébastien Jauliac, Claire Hivroz.   

Abstract

TCR down-modulation following binding to MHC/peptide complexes is considered to be instrumental for T cell activation because it allows serial triggering of receptors and the desensitization of stimulated cells. We studied CD3/TCR down-modulation and zeta degradation in T cells from two ZAP-70-immunodeficient patients. We show that, at high occupancy of the TCR, down-modulation of the CD3/TCR is comparable whether T cells express or do not express ZAP-70. However, if TCR occupancy was low, we found that CD3/TCR was down-regulated to a lesser extent in ZAP-70-negative than in ZAP-70-positive T cells. We studied CD3/TCR down-modulation in P116 (a ZAP-70-negative Jurkat cell-derived clone) and in P116 transfected with genes encoding the wild-type or a kinase-dead form of ZAP-70. Down-modulation of the TCR at high occupancy did not require ZAP-70, whereas at low TCR occupancy down-modulation was markedly reduced in the absence of ZAP-70 and in cells expressing a dead kinase mutant of ZAP-70. Thus, the presence of ZAP-70 alone is not sufficient for down-modulation; the kinase activity of this molecule is also required. The degradation of zeta induced by TCR triggering is also severely impaired in T cells from ZAP-70-deficient patients, P116 cells, and P116 cells expressing a kinase-dead form of ZAP-70. This defect in TCR-induced zeta degradation is observed at low and high levels of TCR occupancy. Our results identify ZAP-70, a tyrosine kinase known to be crucial for T cell activation, as a key player in TCR down-modulation and zeta degradation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165490     DOI: 10.4049/jimmunol.169.4.1705

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Cbl- and Nedd4-family ubiquitin ligases: balancing tolerance and immunity.

Authors:  Denise L Gay; Hilda Ramón; Paula M Oliver
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  Domain analyses of the Runx1 transcription factor responsible for modulating T-cell receptor-beta/CD4 and interleukin-4/interferon-gamma expression in CD4(+) peripheral T lymphocytes.

Authors:  Ryuji Uchino
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

Review 3.  ZAP70: a master regulator of adaptive immunity.

Authors:  Alain Fischer; Capucine Picard; Karine Chemin; Stéphanie Dogniaux; Françoise le Deist; Claire Hivroz
Journal:  Semin Immunopathol       Date:  2010-02-05       Impact factor: 9.623

4.  RhoH regulates subcellular localization of ZAP-70 and Lck in T cell receptor signaling.

Authors:  Hee-Don Chae; Jamie E Siefring; David A Hildeman; Yi Gu; David A Williams
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

5.  Centrosome docking at the immunological synapse is controlled by Lck signaling.

Authors:  Andy Tsun; Ihjaaz Qureshi; Jane C Stinchcombe; Misty R Jenkins; Maike de la Roche; Joanna Kleczkowska; Rose Zamoyska; Gillian M Griffiths
Journal:  J Cell Biol       Date:  2011-02-21       Impact factor: 10.539

Review 6.  Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?

Authors:  Marian Nassef Kadry Naguib Roufaiel; James W Wells; Raymond J Steptoe
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

Review 7.  Vesicular Trafficking to the Immune Synapse: How to Assemble Receptor-Tailored Pathways from a Basic Building Set.

Authors:  Anna Onnis; Francesca Finetti; Cosima T Baldari
Journal:  Front Immunol       Date:  2016-02-15       Impact factor: 7.561

8.  Integrated analysis of lncRNA, miRNA and mRNA profiles reveals potential lncRNA functions during early HIV infection.

Authors:  Lianwei Ma; Hui Zhang; Yue Zhang; Hailong Li; Minghui An; Bin Zhao; Haibo Ding; Junjie Xu; Hong Shang; Xiaoxu Han
Journal:  J Transl Med       Date:  2021-04-01       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.